POLN Polyphor

Spexis to host business update conference call on October 9, 2023

Spexis to host business update conference call on October 9, 2023

ALLSCHWIL, Switzerland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT.

Jeffrey D. Wager, M.D. (CEO & Chairman) will provide strategic business and financial updates. To access the conference call please use the following details:

France:

Germany: 0

Italy:

Switzerland

United Kingdom

United States

International Toll Free

Event Title: Spexis AG – Business Update Conference Call

The conference call will also be available via webcast: 

After the call, a replay of the webcast will be available via the above link.

About Spexis

Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: .

For further information please contact:

For Investors: 

Hernan Levett

Chief Financial Officer

Spexis AG.

0

Or

Stephen Jasper

Managing Director

Gilmartin Group

For Media: 

Dr. Stephan Feldhaus

Feldhaus & Partner

6



EN
06/10/2023

Underlying

POLNPolyphor

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Polyphor

 PRESS RELEASE
Free
POLN POLYPHOR

Spexis Announces Changes to the Executive Committee

Spexis Announces Changes to the Executive Committee Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that Hernan Levett, currently Chief Financial Officer, has decided to pursue a new career opportunity outside the company. He will continue to support the company as a strategic advisor on financial transactions and will depart the company effective December 1, 2023. Martin Jakobovic, curren...

November 1, 2023 1 EN
 PRESS RELEASE
Free
POLN POLYPHOR

Spexis to host business update conference call on October 9, 2023

Spexis AG / Key word(s): Statement Spexis to host business update conference call on October 9, 2023 06.10.2023 / 07:30 CET/CEST     Spexis to host business update conference call on October 9, 2023   Allschwil, Switzerland, October 6, 2023   Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT. Jeffrey D. Wager, M.D. (CEO & Chairman) will provide strategic business and financial updates. ...

October 6, 2023 1 EN
 PRESS RELEASE
Free
POLN POLYPHOR

Spexis to host business update conference call on October 9, 2023

Spexis to host business update conference call on October 9, 2023 ALLSCHWIL, Switzerland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT. Jeffrey D. Wager, M.D. (CEO & Chairman) will provide strategic business and financial updates. To access the conference call please use the following details: France: Germany: 0Italy: Switzerland United Kingdom United States In...

October 6, 2023 1 EN
 PRESS RELEASE
Free
POLN POLYPHOR

Spexis provides business update and announces financial results for th...

Spexis provides business update and announces financial results for the first half of 2023 Ad hoc announcement pursuant to Art. 53 LR Balixafortide, a potent CXCR4 inhibitor, to be evaluated for the treatment of pancreatic ductal adenocarcinoma (PDAC)Spexis closed capital commitments totaling USD $7.5 million supporting Phase 3 ColiFin® program in cystic fibrosis (CF) infectionsCOPILOT study expected to initiate in fourth quarter 2023Appointed Gonçalo Bernardes, PhD, as acting Head of Chemical BiologyAnnounced strong safety and pharmacokinetics results from first-in-human study wit...

September 29, 2023 1 EN
 PRESS RELEASE
Free
POLN POLYPHOR

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as actin...

Spexis AG / Key word(s): Statement Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology 28.09.2023 / 07:30 CET/CEST Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology   Allschwil, Switzerland, September 28, 2023 Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the company has appointed Gonçalo Bernardes, PhD, as acting Head of Chemical Biology. Dr. Bernardes is a leader in the fields of chemistry and oncolog...

September 28, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch